Who
Svetlana Lucas
Director
Company insider
Files Form 4 as: Director, Jasper Therapeutics; Chief Business Officer, Scribe Therapeutics; Director, aTyr Pharma.
In numbers
- Trades disclosed
- 25
- Buys
- 2
- Sells
- 0
- Bought
- $139K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 28 Jun 2019
- Last trade
- 31 Jul 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Sep 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jul 2026filed 4 Aug 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 31 Jul 2026filed 4 Aug 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | SCTX Scribe TherapeuticsBiotechnology | SEC FORM 4 Bought | $45K3,000 at $15.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —109,426 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —109,426 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —109,426 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —109,426 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | SCTX Scribe TherapeuticsBiotechnology | SEC FORM 4 Bought | $45K3,000 at $15.00 | filing |
| 11 May 2026filed 13 May 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 13 Mar 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,547 at $0.00 | filing |
| 13 Mar 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,547 at $0.00 | filing |
| 22 Sep 2025filed 24 Sep 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —20,000 | filing |
| 22 Sep 2025filed 24 Sep 2025 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Bought | $49K20,000 at $2.43 | filing |
| 3 Jul 2025filed 3 Jul 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 1 May 2025filed 2 May 2025 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 22 May 2024filed 23 May 2024 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 17 May 2023filed 19 May 2023 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 26 Apr 2023filed 28 Apr 2023 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.